FRONTEO Co., Ltd. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) announces the release of medical paper search AI "KIBIT Amanogawa ver. 2023" on July 7, 7. .

　KIBIT Amanogawais a paper search AI system that uses FRONTEO's unique natural language processing AI technology.When you enter words, sentences, hypotheses, etc. that you want to look up, AI instantly detects and analyzes related papers from the data of more than 3000 million papers posted on PubMed*. The use of AI has streamlined the search and analysis of papers, which used to take a huge amount of time by humans. At the same time, information that is not biased by the searcher and unknown information that could not be found by conventional keyword searches can be obtained. It will be possible to find it, and support new ideas and discoveries of researchers that lead to innovation.

　In this version upgrade, when the user selects an arbitrary area on the main screen "Space Map", the top 100 papers included in that area that are highly relevant to the search term or text are displayed in a list format. function will be added (Fig. 1).This makes it easier to check the details of the search results displayed on the Space Map.In addition, when the check box is selected in the "Card Box" that displays a list of searched papers, a dot indicating the paper is highlighted on the Space Map, making it easy to locate the paper within the overall search results. (Fig. 2).

　FRONTEO will continue to improve the functionality and usability of AI application solutions, improve the efficiency of medical and pharmaceutical research, promote DX (digital transformation), and contribute to improving the quality of medical care and the QOL of patients.

　The impact of this matter alone on the Company's business performance will be minor.

*Biomedical article database operated by the National Center for Biological Sciences Information, National Library of Medicine

■ About FRONTEO　URL:https://www.fronteo.com/
FRONTEO is a data analysis company that provides various AI solutions and services using the in-house developed AI engine "KIBIT". Based on the philosophy of "providing solutions that do not overlook risks and opportunities buried in records and realizing fairness in the information society," extract meaningful and important information from vast amounts of text data and complex networks. Our strengths are natural language processing and network analysis technologies that support advanced judgments by experts.We are developing businesses in the areas of legal tech AI, business intelligence, life science AI, and economic security, and contributing to solving various corporate and social issues. Founded in August 2003, listed on Tokyo Stock Exchange Mothers (currently Tokyo Stock Exchange Growth) on June 8, 2007.The company operates in Japan, the United States, South Korea, and Taiwan.Acquisition of first-class medical device manufacturing and sales business license, notification of controlled medical device sales business.Capital 6 yen (as of March 26, 3,042,317).

*FRONTEO, KIBIT, and Amanogawa are registered trademarks of FRONTEO in Japan.